News Search Results
Jan 15, 2026, 09:53 ET Turret Capital Launches Sable, a Biotech-Driven Beauty Brand Advancing Body Contouring and Aesthetic Longevity
Capital is a global venture capital firm that specializes in identifying and commercializing transformative healthcare technologies. With a focus on biotechnology and medical innovation, Turret creates and scales companies that address significant unmet needs in human health and wellness.About SOSVSOSV
More news about: Turret Capital Management
Jan 15, 2026, 09:32 ET MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock
More news about: MetaVia, Inc.
Jan 15, 2026, 09:14 ET Junipr Public Relations Named Agency of Record for The Belfry House; R-to-V Marketing to Lead Digital Strategy
founded in 2019, the company has grown to service B2C and B2B clients across a variety of sectors including the hospitality, food and beverage, biotechnology, CPG, food safety, nonprofit, automotive, and cannabis industries. With a passion to do Smart Work for Nice People™, Junipr's skilled team of strategic
More news about: Junipr Public Relations
Jan 15, 2026, 08:59 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
aXichem AB (publ), (aXichem), the developer of innovative feed additives and food supplement biotechnology, is pleased to announce the formal publication of its latest clinical trial,
More news about: aXichem AB
Jan 15, 2026, 08:55 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
aXichem AB (publ), (aXichem), the developer of innovative feed additives and food supplement biotechnology, is pleased to announce the formal publication of its latest clinical trial,
More news about: aXichem AB
Jan 15, 2026, 08:30 ET Continuous Biologics Manufacturing for Modular and Sustainable Operations, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 15, 2026, 08:30 ET Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 15, 2026, 08:30 ET Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
significant in light of the BIOSECURE Act, signed into law on December 18, 2025, which restricts U.S. executive agencies from contracting with "Biotechnology Companies of Concern". By establishing a secure, domestic manufacturing footprint in California through Zylidac Bio LLC, Zydus provides a "safe-harbor"
More news about: Zydus Lifesciences Limited
Jan 15, 2026, 07:00 ET Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
BOSTON, Jan. 15, 2026 /PRNewswire/ -- Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) clinical study
More news about: Brenig Therapeutics Inc
Jan 15, 2026, 06:01 ET First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer
financing round in 2024. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics Limited
Jan 15, 2026, 04:51 ET Aphranel Convenes Cadaver Dissection Class in Thailand Successfully
https://www.prnewswire.com/news-releases/aphranel-convenes-cadaver-dissection-class-in-thailand-successfully-302662229.htmlSOURCE SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
Jan 14, 2026, 22:34 ET Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
Hyundai Bioscience:Hyundai Bioscience is a biotechnology company focused on developing novel drug delivery systems (DDS) to repurpose existing drugs for new therapeutic applications. The company is a member
More news about: Hyundai Bioscience
Jan 14, 2026, 17:10 ET Transneural Therapeutics Presents Preclinical Data on Lead Candidate TN-001 at 64th Annual Meeting of ACNP (2026)
Transneural Therapeutics, Inc. (Transneural), a neuroscience-focused biotechnology company aiming to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel pharmacotherapies, today presented new data
More news about: Transneural Therapeutics, Inc.
Jan 14, 2026, 15:00 ET EDETEK Launches "Ensemble" AI Managed Services to Simplify Adoption of AI and Accelerate Clinical Development
development.About EDETEKFounded in 2009, EDETEK provides AI powered platforms and clinical services to pharmaceutical, biotechnology, and medical device companies worldwide. The company serves more than one hundred and twenty biopharma clients across four continents with a focus
More news about: EDETEK, Inc.
Jan 14, 2026, 12:38 ET Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
/PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide
More news about: Innovative Molecules GmbH
Jan 14, 2026, 12:35 ET Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
/PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide
More news about: Innovative Molecules GmbH
Jan 14, 2026, 10:30 ET Pharmaceutical Filtration Consumables Market worth $18.03 billion by 2030 | MarketsandMarkets™
(Sweden).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 14, 2026, 09:00 ET Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
focused on veterinary biologics, pet nutrition, and animal wellness.At UCLA, Yuyu Venture Studio has spun off two subsidiaries. Yuyu Bio is a biotechnology company developing feline-specific biologics for chronic and underserved conditions, while Mervyn's Petcare is a cat-only health supplement company
More news about: Yuyu Pharma
Jan 14, 2026, 09:00 ET L.E.K. Consulting Announces Seven Promotions to Partner
transaction support across the agribusiness value chain. Garrigues has deep expertise in crop inputs, produce, food ingredients and industrial biotechnology. He holds an A.B. in biomechanical engineering from Harvard University and a Ph.D. in biomedical engineering from Duke University.
More news about: L.E.K. Consulting
Jan 14, 2026, 07:00 ET GitGuardian Closes 2025 with Strong Enterprise Momentum, Protecting Millions of Developers Worldwide
technology-enabled mobility and delivery platform with 30,000+ employees worldwide headquartered in the USAA global pharmaceutical and biotechnology company with 90,000+ employees, headquartered in EuropeA major enterprise software vendor with 110,000+ employeesLeading financial
More news about: GitGuardian
Jan 13, 2026, 19:01 ET ElpasBio and Fosun Kairos Announce Commercialization Collaboration for AlloJoin® Stem Cell Therapy
SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos for the commercialization
More news about: ElpasBio Holdings
Jan 13, 2026, 18:46 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
www.lottebiologics.com About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell
More news about: LOTTE BIOLOGICS
Jan 13, 2026, 18:00 ET Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
requirements and ensuring stable supply for customers worldwide.About Rakuten Medical, Inc.Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell
More news about: Rakuten Medical, Inc.
Jan 13, 2026, 12:36 ET FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
CLICK HERE.Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.The complaint alleges that, throughout the Class Period, Defendants
More news about: Berger Montague
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 140 pharmaceutical and biotechnology companies, generating more than 650 therapeutic programs, 89 clinical programs, and 6 approved products. The Adimab technology has been transferred
More news about: Adimab, LLC